BioTelemetry, now a Royal Phillips company, agreed to pay $44.875 million to settle allegations that the company improperly billed Medicare by outsourcing heart monitoring services to India between 2013 and 2022.
The company was supposed to perform heart monitoring services in the U.S., and BioTelemetry faces allegations that clinicians in India were not properly certified in performing the monitoring, according to a Dec. 21 news release from law firm Ross Feller Casey.
Fewer than 3 percent of the technicians who reviewed the data of the U.S. Medicare patients were properly certified, the release said.
The fraud allegations came to light through a whistleblower lawsuit brought against the company by Ross Feller Casey on behalf of former employees.